ADA and severe combined immunodeficiency: Despite relying on an early γ‐retroviral vector design, HSC GT for one type of PID, Adenosine Deaminase Severe Combined Immunodeficiency (ADA‐SCID), has uniquely and consistently proven safe and has become the first ex vivo GT drug now available on the EU market (Aiuti et al, 2017).